Induced Pluripotent Stem Cell (iPSC)

Global Induced Pluripotent Stem Cell (iPSC) Market to Reach US$3.2 Billion by 2030

The global market for Induced Pluripotent Stem Cell (iPSC) estimated at US$2.1 Billion in the year 2024, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Vascular Cells, one of the segments analyzed in the report, is expected to record a 7.5% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Cardiac Cells segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$937.7 Million While China is Forecast to Grow at 8.9% CAGR

The Induced Pluripotent Stem Cell (iPSC) market in the U.S. is estimated at US$937.7 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$116.8 Million by the year 2030 trailing a CAGR of 8.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.7% CAGR.

Global Induced Pluripotent Stem Cell (iPSC) Market - Key Trends & Drivers Summarized

What Are Induced Pluripotent Stem Cells (iPSCs) and Their Breakthrough Potential?

Induced pluripotent stem cells (iPSCs) are a type of stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka in 2006, who demonstrated that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. These cells possess the ability to develop into almost any type of cell within the human body, akin to embryonic stem cells, but without the associated ethical issues since they do not require the use of embryos. This groundbreaking discovery has opened up new avenues in regenerative medicine, drug discovery, and disease modeling. iPSCs are particularly promising for the development of patient-specific therapies where cells derived from the patients themselves can be used to treat a variety of conditions, from spinal cord injuries to Parkinson’s disease, potentially revolutionizing personalized medicine.

How Are iPSCs Revolutionizing Medical Research and Treatment?

The versatility of iPSCs has made them a valuable tool in the field of medical research and treatment. By reprogramming cells from patients with specific genetic disorders, scientists can create iPSCs that contain the same genetic anomalies. These iPSCs can then be used to study the pathology of diseases at a cellular level, providing insights that are not possible with other types of cells. For instance, iPSCs have been used to model diseases such as ALS, diabetes, and Alzheimer’s, allowing researchers to understand disease mechanisms and discover potential drug targets. Moreover, in the realm of drug testing, iPSCs can be used to evaluate the efficacy and safety of new pharmaceuticals before they are tested in humans, reducing the reliance on animal testing and improving the predictability of drug responses. These applications not only enhance our understanding of complex diseases but also pave the way for more effective and safer treatments.

What Technological Advancements Are Propelling iPSC Research?

Advancements in gene editing and tissue engineering are propelling the research and applications of iPSCs. The integration of CRISPR/Cas9 technology with iPSC technology has enabled precise alterations at the genetic level, enhancing the potential of iPSCs in therapeutic development and disease modeling. Researchers can now correct genetic defects in iPSCs derived from patients, potentially leading to cell therapy solutions that could cure inherited diseases. Additionally, the development of 3D bioprinting technologies allows for the construction of complex tissues from iPSCs, which could one day lead to the creation of organs for transplant. These technological innovations are crucial for overcoming current limitations in iPSC research, such as the efficiency of cell reprogramming and the maturity of differentiated cells, making these cells more viable for clinical applications.

What Drives the Rapid Expansion of the iPSC Market?

The growth in the iPSC market is driven by several factors, including significant advancements in biomedical research and an increasing emphasis on personalized medicine. The potential of iPSCs to provide patient-specific cells for therapy and research has led to substantial investment from both public and private sectors. The expansion of regenerative medicine, seeking to restore or establish normal function by replacing damaged cells, tissues, or organs, heavily relies on innovations in iPSC technology. Moreover, the growing prevalence of chronic diseases and genetic disorders increases the demand for novel treatment strategies that iPSCs could fulfill. Additionally, regulatory support and ethical acceptance of iPSCs compared to embryonic stem cells encourage further development and application of this technology. These drivers collectively foster a dynamic and rapidly advancing market, promising to revolutionize healthcare and treatment paradigms in the coming years.

SCOPE OF STUDY:

The report analyzes the Induced Pluripotent Stem Cell (iPSC) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Cell Type (Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells, Other Cell Types); Research Method (Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering, Other Research Methods); Application (Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine, Other Applications)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 51 Featured) -

• Lonza Group Ltd.
• Evotec SE
• FUJIFILM Holdings Corporation
• Abcam PLC
• Horizon Discovery Ltd.
• Cell Signaling Technology, Inc.
• Cell Applications, Inc.
• Invivogen
• ALSTEM, LLC
• Censo Biotechnologies Ltd.
• Creative Bioarray
• Creative Biolabs
• Axol Bioscience Ltd.
• ID Pharma Co., Ltd.
• BlueRock Therapeutics, LLC

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.